Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.

MLA

Vekhova, Ksenia A., et al. “Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.” Clinical Pharmacology and Therapeutics, Oct. 2024. EBSCOhost, https://doi.org/10.1002/cpt.3478.

APA

Vekhova, K. A., Namiot, E. D., Jonsson, J., & Schiöth, H. B. (2024). Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations. Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.3478

Chicago

Vekhova, Ksenia A, Eugenia D Namiot, Jörgen Jonsson, and Helgi B Schiöth. 2024. “Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.” Clinical Pharmacology and Therapeutics, October. doi:10.1002/cpt.3478.